Prediction of major bleeding events in 1381 patients with essential thrombocythemia.

International journal of hematology 2023 Nov

filter terms:

The goal of therapy in essential thrombocythemia (ET) is reducing thrombotic risk. No algorithm to predict hemorrhage risk exists. The impact ofanti-platelet, cytoreductive and anticoagulation therapies on risk of major bleeding (MB) was evaluated. MB events were retrospectively analyzed in 1381 ET from 10 European centers. There were 0.286 MB events/person-year. Neither the International Thrombosis Prognostic Score for thrombosis in essential thrombocythemia (IPSET-t) nor the revised IPSET-t (r-IPSET-t) was predictive for hemorrhage-free survival at 10 years (p = 0.092 vs p = 0.1). Ageand leukocyte count were MB risk factors, while low hemoglobin was protective. For ET with extreme thrombocytosis (ExtT) and leukocytosis cytoreduction was not protective. MB were more frequent in ET with ExtT who received anticoagulation. Antiplatelet therapy was not, while anticoagulation was a risk factor for MB (HR 3.05, p = 0.016, CI 1.23-7.56), in particular vitamin K antagonists (22.6% of those treated had a MB event, HR 2.96, p = 0.004, CI 1.41-6.22). Survival at 10 years was associated with hemorrhage (OR 2.54, p < 0.001) but not thrombosis (HR 0.95, p = 0.829). Hemorrhage has a higher risk of mortality than thrombosis. Improved risk stratification for MB is necessary. The choice of anticoagulation, cytoreduction and antiplatelet therapies is an important area of research in ET. © 2023. The Author(s).

Citation

Ruth Stuckey, Jean-Christophe Ianotto, Marco Santoro, Anna Czyż, Manuel M Perez Encinas, María Teresa Gómez-Casares, Maria Soledad Noya Pereira, Anna Kulikowska de Nałęcz, Aleksandra Gołos, Krzysztof Lewandowski, Łukasz Szukalski, Jesús M González-Martín, Marta Anna Sobas. Prediction of major bleeding events in 1381 patients with essential thrombocythemia. International journal of hematology. 2023 Nov;118(5):589-595